Konstantinos Vanezis
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.
Journal: Frontiers in medicine
Published: February 18, 2026
Interleukin 11 therapy causes acute left ventricular dysfunction.
Journal: Cardiovascular research
Published: June 25, 2024
The Effect of Interleukin-10 Immunotherapy on Renal Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis of Preclinical Studies.
Journal: International journal of molecular sciences
Published: April 17, 2024
Cardiomyocyte-Restricted Expression of IL11 Causes Cardiac Fibrosis, Inflammation, and Dysfunction.
Journal: International journal of molecular sciences
Published: July 17, 2023
Correction to: LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide.
Journal: Journal of cardiovascular translational research
Published: July 14, 2022
LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide.
Journal: Journal of cardiovascular translational research
Published: December 15, 2021
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo.
Journal: The Biochemical journal
Published: August 11, 2021
Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models.
Journal: Scientific reports
Published: June 03, 2020
Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads.
Journal: Epigenetics & chromatin
Published: September 13, 2017
Last Updated: 09/26/2026